Immuno-oncology
Conference Coverage
Enoblituzumab plus pembrolizumab shows promise for select solid tumors
WASHINGTON – Combination enoblituzumab and pembrolizumab showed acceptable safety and encouraging antitumor activity in select patients with B7-H3...
Conference Coverage
Immunotherapy’s cardiac effects require early monitoring, management
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
Conference Coverage
The personal cancer vaccine NEO-PV-01 shows promise in metastatic cancers
WASHINGTON – The NEO-PV-1 neoantigen vaccine plus poly-ICLC adjuvant and nivolumab is well tolerated and shows clinical activity in metastatic...
Conference Coverage
Cancer vaccine fails in CRC but trial yields lessons
SAN FRANCISCO – Tecemotide did not improve recurrence-free or overall survival relative to placebo when given after R0/R1 resection of liver-only...
Conference Coverage
Novel bispecific CAR shows promise in B-cell malignancies
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
Conference Coverage
Uninterrupted ibrutinib with CAR T could improve CLL outcomes
SAN DIEGO – Ibrutinib treatment before and after CAR T-cell therapy in CLL patients may decrease the risk of severe cytokine release syndrome.
From the Journals
Avelumab active in recurrent or refractory ovarian cancer
Another cancer immunotherapy agent has positive results in ovarian cancer, which supports ongoing investigations of this checkpoint inhibitor in...
Conference Coverage
Pembrolizumab bests chemo in PD-L1-positive esophageal cancer
SAN FRANCISCO – In KEYNOTE-181, second-line pembrolizumab reduced risk of death by 31% relative to chemotherapy among patients whose esophageal...
From the Journals
Checkpoint inhibitors linked to rare, but serious immune-related side effects
The study breaks down the hematological immune-related side effects of checkpoint inhibitors.
Daily News Podcast
Daily News Special: SABCS
The latest clinical medicine news from the 2018 annual San Antonio Breast Cancer Symposium.
From the Journals
Adverse events a potential concern for chemotherapy-nivolumab in advanced gastric cancer
Adverse events led to dose delays or reductions in 95% of patients. Serious adverse events affected 15% of patients and in most cases led them to...